Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
UCLM802
i
Other names:
UCLM 802, UCLM-802, UCLM802, anti-MESO CAR T, mRNA CAR-mesothelin T Cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
UTC Therap
Drug class:
Mesothelin-targeted CAR-T immunotherapy
Related drugs:
‹
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
SynKIR-110 (1)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB103 (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
MSLN-CAR-T cell therapy (3)
ATA3271 (2)
SynKIR-110 (1)
AB-1015 (0)
ATA2271 (0)
BZD1901 (0)
CD40 ligand expressing MSLN-CAR T (0)
GC008t (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
LCAR-M23 (0)
LD013 (0)
MCY-M11 IP (0)
MPTK-CAR-T cells (0)
MSLN CAR-T (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB103 (0)
RD133 (0)
TmMSTN-01 (0)
UCARTMESO (0)
YTS105 (0)
anti- MESO CAR-T cells (0)
anti-mesothelin CAR T cells (0)
iCasp9M28z T cell infusion (0)
meso-CART (0)
mesothelin-targeted CAR-T immunotherapy (0)
multi-target gene-modified CAR-T/TCR-T cell immunotherapy (0)
›
Associations
News
Trials
Filter by
Latest
over1year
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=87, Recruiting, Zhejiang University
over 1 year ago
New P1 trial
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
cyclophosphamide • UCLM802
over1year
MSLN-targeted CAR-T Cells in Solid Tumors. (clinicaltrials.gov)
P1, N=87, Not yet recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
over 1 year ago
New P1 trial • CAR T-Cell Therapy • Metastases
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
UCLM802
almost2years
UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors (clinicaltrials.gov)
P1, N=87, Not yet recruiting, Peking University
almost 2 years ago
New P1 trial • CAR T-Cell Therapy • Metastases
|
IL6 (Interleukin 6) • MSLN (Mesothelin) • IL10 (Interleukin 10)
|
cyclophosphamide • UCLM802
almost2years
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=0, Withdrawn, Shanghai Pudong Hospital | N=20 --> 0 | Recruiting --> Withdrawn
almost 2 years ago
Enrollment change • Trial withdrawal • CAR T-Cell Therapy • Metastases
|
MSLN (Mesothelin)
|
cyclophosphamide • fludarabine IV • UCLM802
over2years
Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors (clinicaltrials.gov)
P1, N=20, Recruiting, Shanghai Pudong Hospital
over 2 years ago
New P1 trial • CAR T-Cell Therapy
|
MSLN (Mesothelin)
|
cyclophosphamide • fludarabine IV • UCLM802
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login